Thrombin-Activatable Fibrinolysis Inhibitor, Human

Native thrombin-activatable fibrinolysis inhibitor from human liver. Single chain glycoprotein synthesized in the liver. ctivated by the thrombin/thrombomodulin complex by proteolytic cleavage at Arg⁹². Circulates in plasma as a zymogen at a concentration of about 50 nM. Believed to play an important role in the interaction between procoagulant, anticoagulant, and fibrinolytic systems.

Please refer to vial label for lot-specific concentration.

In 150 mM NaCl, 20 mM HEPES, pH 7.4.

Following initial thaw, aliquot and freeze (-70°C).

Prepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Boffa, M.B., et al. 1999. Biochemistry 38, 6547.
Boffa, M.B., et al. 1998. J. Biol. Chem. 273, 2127.
Bajzar, L., et al. 1995. J. Biol. Chem. 270, 14477.

One unit is defined as the amount of enzyme that will hydrolyze 1 µM Hip-L-Arg per min at 25°C, pH 7.65.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)